EGFR and head and neck squamous cell carcinoma: Although few patients benefit from cetuximab, which is the only EGFR-targeted drug approved for the treatment of HNSCC, because not all cases of HNSCC are dependent on EGFR [1], cetuximab in combination with radiation therapy improves overall survival of HNSCC patients.